Patents by Inventor James R. Falsey

James R. Falsey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12214051
    Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: February 4, 2025
    Assignee: Amgen Inc.
    Inventors: Yuan Cheng, Chawita Netirojjanakul, Jerry Ryan Holder, Bin Wu, James R. Falsey, Bradley J. Herberich, Kelvin Sham, Leslie P. Miranda, Shu-Chen Lu, Murielle M. Venient-Ellison, Shanaka Stanislaus, Junming Yie, Jing Xu
  • Patent number: 10905772
    Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: February 2, 2021
    Assignee: Amgen Inc.
    Inventors: Yuan Cheng, Chawita Netirojjanakul, Jerry Ryan Holder, Bin Wu, James R. Falsey, Bradley J. Herberich, Kelvin Sham, Leslie P. Miranda, Shu-Chen Lu, Murielle M. Veniant-Ellison, Shanaka Stanislaus, Junming Yie, Jing Xu
  • Patent number: 10344060
    Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 9, 2019
    Assignee: AMGEN INC.
    Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda, Kaustav Biswas, Bin Wu, Kelvin Sham, Jason C. Long
  • Patent number: 9636418
    Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 2, 2017
    Assignee: AMGEN INC.
    Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda
  • Patent number: 8759532
    Abstract: Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: June 24, 2014
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Kaustav Biswas, Frank Chavez, Jr., Ning Chen, Frenel Fils De Morin, James R. Falsey, Michael J. Frohn, Paul E. Harrington, Daniel B. Home, Essa Hu Harrington, Matthew R. Kaller, Roxanne K. Kunz, Holger Monenschein, Thomas T. Nguyen, Alexander J. Pickrell, Andreas Reichelt, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Guomin Yao
  • Patent number: 8716281
    Abstract: The present invention describes pyrimidine compounds of Formula I that are useful as anaplastic lymphoma kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: May 6, 2014
    Assignee: Amgen Inc.
    Inventors: Marian C. Bryan, Alan C. Cheng, Elizabeth M. Doherty, James R. Falsey, Ingrid M. Fellows, Joseph L. Kim, Richard T. Lewis, Michele H. Potashman, Douglas A. Whittington
  • Patent number: 8637500
    Abstract: Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, X5, X6, X7, X8, and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R2, R3, R4, R5, R6, R7, R9, X1, X2, and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: January 28, 2014
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Ning Chen, James R. Falsey, Michael J. Frohn, Paul E. Harrington, Essa Hu Harrington, Matthew R. Kaller, Roxanne K. Kunz, Thomas T. Nguyen, Alexander J. Pickrell, Andreas Reichelt, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Aaron C. Siegmund, Guomin Yao
  • Patent number: 8497269
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A4, L, R1, R2, R3, R5 and m are as defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, ankylosing spondylitis, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: July 30, 2013
    Assignee: Amgen Inc.
    Inventors: Andrew Tasker, James R. Falsey, Robert M. Rzasa, Bradley J. Herberich, Dawei Zhang
  • Publication number: 20130158019
    Abstract: Compounds of Formula I are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Application
    Filed: May 4, 2011
    Publication date: June 20, 2013
    Applicant: AMGEN INC.
    Inventors: Marian C. Bryan, Alan C. Cheng, Elizabeth M. Doherty, James R. Falsey, Ingrid M. Fellows, Joseph L. Kim, Richard T. Lewis, Michele H. Potashman, Douglas A. Whittington
  • Publication number: 20130079325
    Abstract: Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Application
    Filed: November 14, 2012
    Publication date: March 28, 2013
    Inventors: Jennifer R. Allen, Biswas Kaustav, Frank Chavez, Ning Chen, Frenel Fils De Morin, James R. Falsey, Michael J. Frohn, Paul E. Harrington, Daniel B. Horne, Essa Hu Harrington, Matthew R. Kaller, Roxanne Kunz, Holger Monenschein, Thomas T. Nguyen, Alexander J. Pickrell, Andreas Reichelt, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Guomin Yao
  • Patent number: 8318718
    Abstract: Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: November 27, 2012
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Biswas Kaustav, Frank Chavez, Ning Chen, Frenel Fils De Morin, James R. Falsey, Michael J. Frohn, Paul E. Harrington, Daniel B. Horne, Essa Hu Harrington, Matthew R. Kaller, Roxanne Kunz, Holger Monenschein, Thomas T. Nguyen, Alexander J. Pickrell, Andreas Reichelt, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Guomin Yao
  • Patent number: 8247409
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: August 21, 2012
    Assignee: Amgen Inc.
    Inventors: Fang-Tsao Hong, James R. Falsey, Seifu Tadesse, Andrew Tasker
  • Publication number: 20120040983
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A4, L, R1, R2, R3, R5 and m are as defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, ankylosing spondylitis, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: October 7, 2009
    Publication date: February 16, 2012
    Applicant: Amgen Inc.
    Inventors: Andrew Tasker, James R. Falsey, Robert M. Rzasa, Bradley J. Herberich, Dawei Zhang
  • Publication number: 20110118234
    Abstract: The present invention provides compounds Formula (I) that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: May 4, 2009
    Publication date: May 19, 2011
    Inventors: Kaustav Biswas, Jian J. Chen, James R. Falsey, Vijay Keshav Gore, Qingyian Liu, Vu Van Ma, Stephanie J. Mercede, Robert M. Rzasa, Christopher M. Tegley, Jiawang Zhu
  • Patent number: 7897619
    Abstract: The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: March 1, 2011
    Assignee: Amgen Inc.
    Inventors: Qingping Zeng, Dawei Zhang, Guomin Yao, George E. Wohlhieter, Xianghong Wang, James Rider, Andreas Reichelt, Holger Monenschein, Fang-Tsao Hong, James R. Falsey, Celia Dominguez, Matthew P. Bourbeau, John G. Allen
  • Patent number: 7745449
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: June 29, 2010
    Assignee: Amgen Inc.
    Inventors: Fang-Tsao Hong, James R. Falsey, Robert M. Rzasa, Seifu Tadesse, Andrew Tasker
  • Publication number: 20100160280
    Abstract: Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, X5, X6, X7, X8, and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R2, R3, R4, R5, R6, R7, R9, X1, X2, and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Application
    Filed: December 16, 2009
    Publication date: June 24, 2010
    Applicant: AMGEN INC.
    Inventors: Jennifer R. Allen, Ning Chen, James R. Falsey, Michael Frohn, Paul Harrington, Essa Hu, Matthew R. Kaller, Roxanne Kunz, Stephanie J. Mercede, Thomas T. Nguyen, Alexander J. Pickrell, Andreas Reichelt, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Aaron C. Siegmund, Christopher M. Tegley, Guomin Yao
  • Publication number: 20100125062
    Abstract: Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Application
    Filed: November 16, 2009
    Publication date: May 20, 2010
    Applicant: AMEN INC.
    Inventors: Jennifer R. Allen, Kaustav Biswas, Frank Chavez, Jr., Ning Chen, Frenel Fils Demorin, James R. Falsey, Mike Frohn, Paul Harrington, Dan Horne, Essa Hu, Matthew R. Kaller, Roxanne Kunz, Holger Monenschein, Tom Nguyen, Alex Pickrell, Andreas Reichelt, Shannon Rumfelt, Rob Rzasa, Kelvin Sham, Guomin Yao
  • Publication number: 20100125074
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: November 11, 2009
    Publication date: May 20, 2010
    Applicant: Amgen Inc.
    Inventors: Fang-Tsao Hong, James R. Falsey, Robert M. Rzasa, Seifu Tadesse, Andrew Tasker
  • Patent number: 7511044
    Abstract: Pyrimidine ethers and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea,
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: March 31, 2009
    Assignee: Amgen Inc.
    Inventors: Hui-Ling Wang, Chenera Balan, Elizabeth M. Doherty, James R. Falsey, Vijay Keshav Gore, Jodie Katon, Mark H. Norman